Project Grant R01CA309280
Award Date 8/4/26
Completion Date 7/31/31
Dollars Obligated $739K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $737,082 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop bioinspired virus-like nanovaccines that boost chimeric antigen receptor (CAR) T cell and endogenous T cell responses against solid tumors with antigen heterogeneity. The recipient will develop an autologous tumor cell membrane-coated dual CAR and endogenous T cell boosting virus-like nanoparticle vaccine (DTVLP-VAX) to...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $181,610 on September 1, 2026, to develop and deploy computational methods for creating novel immunotherapies targeting neuroblastoma in children under the Cancer Treatment Research program (CFDA 93.395). The funded work centers on bioinformatics pipeline development and analysis of proteogenomic data to identify new immunotherapeutic targets for pediatric cancer. Under the leadership of Dr. John Maris and...
- The National Cancer Institute awarded ST Jude Children's Research Hospital Inc. $737,023 under the Cancer Treatment Research program (CFDA 93.395) on July 23, 2026, to develop and evaluate CD19-CAR T cell therapy combined with TCR alpha/beta–depleted haploidentical hematopoietic cell transplantation for pediatric patients with relapsed or refractory CD19+ acute lymphoblastic leukemia and lymphoma. The research aims to minimize relapse risk and graft-versus-host disease while eliminating total...
- The National Cancer Institute, a division of the Department of Health and Human Services, awarded $457,683 to The Children's Hospital of Philadelphia on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize a macromolecular prodrug-based delivery strategy for the topoisomerase I inhibitor SN22 designed to overcome tumor defense mechanisms and suppress high-risk neuroblastoma, the most common and deadly solid tumor of childhood. The project targets...
- The National Cancer Institute awarded the University of Pittsburgh $379,644 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to design, synthesize, and test cyclic peptide-based adaptors for programmable universal CAR T cell therapy targeting cancer antigens. The project addresses limitations of current antibody-based adaptors for SNAP-CAR (Snapin-mediated Programmable Antigen Receptor) T cells, which require complex chemical modifications, high production costs, and...
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $703,071 on April 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define the determinants of long-term CAR-T cell persistence in blood cancer patients. The research identifies the cellular and molecular properties of CAR-T cells that sustain durable anti-tumor function years after infusion. Prior work by the investigative team revealed that long-lived CAR-T cells up to five years...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded The Trustees of The University of Pennsylvania $668,864 on June 15, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development of a biomarker to predict patient response to chimeric antigen receptor (CAR) T cell therapy for glioblastoma and to identify mechanisms of tumor resistance to CAR T treatment. The research employs...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $263,656 on August 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research into novel mechanisms of acute myeloid leukemia (AML) resistance to chimeric antigen receptor T cell (CAR-T) therapy. The research aims to develop a detailed understanding of how altered STAT5 levels dictate poor outcomes for AML CAR-T therapies and to identify a combination therapy that selectively blocks AML...
- The National Cancer Institute awarded The Trustees of The University of Pennsylvania $704,044 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms by which EZH2 inhibition enhances adoptive T-cell therapies for cancer. The research addresses resistance to CAR-T cell therapy, where only one-third of non-Hodgkin lymphoma patients receiving anti-CD19 CAR-T treatments achieve lasting remission. The project centers on the epigenetic modulator EZH2 and...
- The National Cancer Institute awarded The Children's Hospital of Philadelphia $350,860 on September 1, 2026, through a Cooperative Agreement (UH2CA312695) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to implement exome capture-based RNA sequencing for real-time clinical risk stratification in pediatric B-cell acute lymphoblastic leukemia (B-ALL) treatment. The recipient will establish centralized diagnostic RNA sequencing-based molecular classification across three...